Abstract: Morbihan disease is a rare condition characterized by chronic and persistent erythematous solid edema localized on the face. It is believed to be a complication of rosacea and may occur at any stage of the disease. Features of this condition include variable therapeutic response and great refractoriness. We report a case of a 61-year-old man with rosacea history diagnosed with Morbihan disease, who showed excellent therapeutic response with the combination of deflazacort and oral isotretinoin but developed recurrence after corticosteroid discontinuation. We believe that in severe cases of lymphedema of the face this combination is effective and corticosteroid suspension should be done slowly and gradually.
INTRODUCTION
Morbihan disease is a rare entity with only a few cases reported in the literature. It is characterized by a chronic and recurrent pattern of erythema and symmetrical facial edema, mainly located in the middle and upper thirds of the face (malar regions, nose, glabella, eyelids, and forehead). The evolution of the condition results in deformity of facial contours and even in visual changes.
1

CASE REPORT
A 61-year-old Caucasian man reported a 20-year history of rosacea, which evolved over the past two years to erythematous, with painless and persistent edema on the face ( Figure 1 ). He complained of a hot sensation on his face and was unhappy with the cosmetic aspect. He reported no visual complaints. He had previously been treated with oral isotretinoin for six months (he was not able to inform the dose he used), with partial response during use and relapse after drug suspension. Laboratory tests were normal. Histopathological examination is shown in Figure 2 . The patient started on isotretinoin (20mg -0.3mg/kg) and deflazacort (30mg) with excellent therapeutic response after one month ( Figure 3 ). Isotretinoin was maintained, and the corticosteroid was discontinued after one month of use, with recurrence occurring within a few days. Topical metronidazole and later oral metronidazole were then associated, but we observed no improvement. We increased the dose of isotretinoin to 40mg (0.5mg/kg), but with no improvement either. Finally, we reintroduced the systemic corticosteroid (deflazacort 30mg/ daily) and maintained isotretinoin (20mg/daily), with significant improvement of the erythema and lymphedema of the face, recommending that a slow and gradual withdrawal of the medication should be done. persistent facial edema, and morbus Morbihan. 2, 4 The typical finding of Morbihan's disease is non-depressive edema of the upper two thirds of the face, with no tendency for spontaneous regression. 5 However, pitting edema may be evident in its early stages and the typical solid edema appears after fibrotic induration that occurs due to recurrent inflammation. 2, 6 The facial erythema is described as poorly defined or as discrete patches or isolated plaques. 2 Its evolution is initially fluctuating but becomes permanent with time, leading to disfigurement of facial contours. 7 Eye involvement with rosacea is common, especially in the form of blepharitis and conjunctivitis. Although reported, lymphedema of the eyelids is a rare complication. Smith and Cohen showed good results with isotretinoin alone (40mg-80mg/day) for a prolonged period (9-24 months), with no documented recurrence in the five patients reported. 2 Our patient showed no significant improvement with isotretinoin alone. Other studies report the association of isotretinoin with ketotifen or clofazimine, prednisolone with metronidazole and ketotifen, and doxycycline with prednisolone, with variable outcomes. 5, 7, 9, 10 The association of deflazacort with oral isotretinoin, a regimen used in our study, was not found in the literature. Despite the excellent therapeutic response, we observed a relapse after corticosteroid suspension after one month of use. We believe that in severe cases, with significant lymphedema of the face, like that of our patient, corticosteroid withdrawal should be slow and gradual. Surgical procedures, such as blepharoplasty, may be useful in refractive cases. 5 The pathogenesis of Morbihan disease is still unclear. Only a few therapeutic options are reported with uncertain results and a high index of refractory cases. However, we believe that early diagnosis and treatment are essential to avoid irreversible lymphatic damage. The association of deflazacort with isotretinoin showed to be effective in our patient, but we should monitor him longer to observe possible relapse after the suspension of treatment. q
DISCUSSION
